Self-Assembled Solutions to Asymmetric Hydrogenation

描述(由申请人提供)：这项提议采用了一种新的催化不对称氢化策略，该策略基于手性配体的金属导向多组分自组装。组合策略在配体支架生成步骤中使用自组装来产生新的手性双齿配体的库，特别是手性自组装配体(SALS)。这一阶段的应用主要集中在设计、制备和评价五种底物类的Rh催化的不对称氢化的文库。在化学发现和工艺研究中，经常会遇到进行高效对映体选择性氢化反应的需要。申请组织Pharmagra Labs，Inc.是一家以化学为基础的公司，为制药、生物技术和农化部门提供定制合成服务。确定的最成功的SALS将用于构建商业的、基础广泛的不对称氢化筛选试剂盒。此外，将开发能力，以进一步优化筛选试剂盒中确定的铅结构(定制配体开发)，并开发大规模重新合成配体的工艺，以满足应用需求(定制配体合成)。

DESCRIPTION (provided by applicant): This proposal exploits a new strategy for catalytic asymmetric hydrogenation based on metal-directed multicomponent self-assembly of chiral ligands. The combinatorial strategy uses self-assembly in the ligand scaffold-generating step to produce libraries of new chiral bidentate ligands, specifically, chiral self-assembled ligands (SALs). This Phase I application focuses on the design, preparation and evaluation of such libraries in five substrate classes of rhodium-catalyzed asymmetric hydrogenation. The need to carry out efficient enantioselective hydrogenation is frequently encountered in chemical discovery and process research. The applicant organization, PharmAgra Labs, Inc., is a chemistry-based company providing custom synthesis services to the pharmaceutical, biotech and agrochemical sectors. The most successful SALs identified will be used to construct a commercial, broad-based screening kit for asymmetric hydrogenation. In addition, capabilities will be developed to further optimize lead structures identified in the screening kit (custom ligand development) and to develop processes for ligand re-synthesis on a scale to meet application demand (custom ligand synthesis).